Investors Buy SPDR S&P Biotech ETF (XBI) on Weakness

Investors purchased shares of SPDR S&P Biotech ETF (NYSEARCA:XBI) on weakness during trading on Friday. $134.75 million flowed into the stock on the tick-up and $56.65 million flowed out of the stock on the tick-down, for a money net flow of $78.10 million into the stock. Of all stocks tracked, SPDR S&P Biotech ETF had the 12th highest net in-flow for the day. SPDR S&P Biotech ETF traded down ($0.16) for the day and closed at $82.00

The company also recently declared a quarterly dividend, which was paid on Thursday, December 27th. Shareholders of record on Monday, December 24th were given a dividend of $0.012 per share. The ex-dividend date was Friday, December 21st. This represents a $0.05 annualized dividend and a yield of 0.06%.

Institutional investors and hedge funds have recently made changes to their positions in the business. Rehmann Capital Advisory Group boosted its position in SPDR S&P Biotech ETF by 33.0% during the 3rd quarter. Rehmann Capital Advisory Group now owns 1,435 shares of the exchange traded fund’s stock valued at $138,000 after buying an additional 356 shares during the period. Moneta Group Investment Advisors LLC purchased a new stake in shares of SPDR S&P Biotech ETF in the 2nd quarter worth about $144,000. Mainstay Capital Management LLC ADV lifted its position in shares of SPDR S&P Biotech ETF by 9,419.3% in the 2nd quarter. Mainstay Capital Management LLC ADV now owns 14,279 shares of the exchange traded fund’s stock worth $150,000 after purchasing an additional 14,129 shares during the period. Proficio Capital Partners LLC purchased a new stake in shares of SPDR S&P Biotech ETF in the 3rd quarter worth about $153,000. Finally, ACG Wealth purchased a new stake in shares of SPDR S&P Biotech ETF in the 3rd quarter worth about $201,000.

TRADEMARK VIOLATION NOTICE: “Investors Buy SPDR S&P Biotech ETF (XBI) on Weakness” was originally published by Transcript Daily and is the property of of Transcript Daily. If you are viewing this report on another site, it was stolen and republished in violation of U.S. & international copyright & trademark law. The original version of this report can be read at https://transcriptdaily.com/2019/01/11/investors-buy-spdr-sp-biotech-etf-xbi-on-weakness.html.

SPDR S&P Biotech ETF Company Profile (NYSEARCA:XBI)

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.

Featured Article: Intrinsic Value

Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply